RESUMEN
Nonalcoholic fatty liver disease (NAFLD) includes a series of diseases affected by various complex factors. Mitochondrial dysfunction often occurs in NAFLD and may lead to the progression of hepatitis and liver fibrosis. This article reviews the important role of mitochondrial oxidative stress, respiration, energy metabolism, quality control, and mitochondrial DNA in NAFLD and summarizes the current status of mitochondria-targeted therapy for NAFLD, hoping to provide a new direction for the research and clinical treatment of NAFLD.
RESUMEN
At present, more and more studies have been conducted on noninvasive diagnostic indicators for liver cirrhosis, but no consensus has been reached on the association of noninvasive diagnostic indicators with clinical outcome events and their predictive value. This article summarizes the value of noninvasive indicators, including serological markers, serum diagnostic models, and liver stiffness measurement (LSM), in predicting the clinical outcome events of liver cirrhosis. The noninvasive diagnostic method of serological markers (such as platelet count and FibroTest) combined with LSM can assess the stage of liver fibrosis and predict the outcome events and long-term prognosis of liver cirrhosis, and thus it has been included in Chinese and global guidelines and has been widely used in clinical practice. The use of new combinations (such as LSM combined with serological markers or diagnostic models) or a step-by-step calculation method shows the hope of modification to realize individualized dynamic clinical management of patients, reduce or avoid the occurrence of clinical outcome events of liver cirrhosis, and bring maximum benefit to patients with liver cirrhosis.